NCT00557206View on ClinicalTrials.gov

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

NeoplasmsHead and Neck Neoplasms

Interventions

DRUG

Oxaliplatin and Docetaxel

"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."

Trial Locations (1)

55417

VA Medical Center, Minneapolis

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Minneapolis Veterans Affairs Medical Center

FED